TITLE

FDA Approvals In April

PUB. DATE
May 2013
SOURCE
BioWorld Insight;5/13/2013, Vol. 21 Issue 20, p7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
A table is presented which lists pharmaceutical companies and their drugs which have been approved by the U.S. Food and Drug Administration (FDA) including Sitavig manufactured by BioAlliance Pharma SA, Amitiza by Sucampo Pharmaceuticals Inc., and Karbinal ER by Tris Pharma Inc. in April, 2013.
ACCESSION #
87619293

 

Related Articles

  • FDA Submissions, Approvals & Other Actions: April 2013.  // BioWorld Insight;5/13/2013, Vol. 21 Issue 20, p27 

    A table is presented on the U.S. Food and Drug Administration (FDA) submissions, approvals & other actions as of April, 2013 which lists pharmaceutical products of several pharmaceutical companies including CytRx Corp., Durect Corp., and Tris Pharma Inc.

  • New Products.  // Drug Topics;Feb2010, Vol. 154 Issue 2, p44 

    The article offers updates related to drugs in the U.S. The Food and Drug Administration (FDA) has approved Clonidine ER suspension and Clonidine ER tablets from Tris Pharma. Sandoz Pharmaceutical Corp. has introduced the calcipotriene solution 0.005%. Eli Lilly & Co. revealed that the FDA has...

  • Sucampo's Amitiza Gets FDA Nod in IBS with Constipation. Boggs, Jennifer // BioWorld Today;5/1/2008, Vol. 19 Issue 85, p1 

    The article reports on the approval of the drug Amitiza (lubiprostone) of Sucampo Pharmaceuticals Inc., by the U.S. Food and Drug Administration for female patients with constipation-predominant irritable bowel syndrome (IBS-C). It is stated that this is the only U.S.-approved drug for that...

  • Sucampo's Amitiza Gets FDA Nod and Payment.  // Bioworld Week;5/5/2008, Vol. 16 Issue 18, p1 

    The article reports on the FDA approval gained by Bethesda, Maryland-based Sucampo Pharmaceuticals Inc.'s Amitiza (lubiprostone) for female patients with constipation-predominant irritable bowel syndrome (IBS-C). The approval makes it the only U.S.-approved drug for that indication following the...

  • NEW PRODUCT NEWSWIRE.  // Drug Topics;3/6/2006, Vol. 150 Issue 5, p50 

    The article presents several new drugs from various pharmaceutical firms in the U.S. Sucampo Pharmaceutical Inc. markets newly approved Amitiza which is indicated for the treatment of chronic adult idiopathic constipation. ISTA Pharmaceuticals' Xibrom approved for the treatment of ocular...

  • GENERICS NEWSLINE.  // Monthly Prescribing Reference;Oct2012, Vol. 28 Issue 10, pA-12 

    The article offers news briefs related to generic drugs as of September 19, 2012. Watson Inc. has announced the U.S. Food and Drug Administration's (FDA's) approval of their Abbreviated New Drug Application (ANDA) for Lidocaine Topical Patch 5%, generic version of Endo Pharmaceuticals' Lidoderm....

  • REPORTERS Notebook.  // Drug Store News;5/19/2008, Vol. 30 Issue 6, p16 

    The article offers news briefs in the U.S. Takeda and Sucampo Pharmaceuticals' product, Amitiza, for constipation was approved by the Food and Drug Administration (FDA) for women over 18 years of age. The FDA has approved GlaxoSmithKline's asthma drug Advair to be used widely to treat patients...

  • CLINIC ROUNDUP.  // BioWorld Today;3/14/2007, Vol. 18 Issue 50, p6 

    The article offers news about the biopharmaceutical industry. An investigational new drug application was filed by Ambrilia Biopharma Inc. and Mallinckrodt Inc. with the Food and Drug Administration (FDA). A Phase 1 trial of CeNeRx BioPharma Incorporated's drug candidate for depression and...

  • Pipeline.  // Medical Marketing & Media;Jun2008, Vol. 43 Issue 6, p12 

    The article offers news briefs related to the approval of drugs. GlaxoSmithKline and Pozen Inc. have announced the U.S. Food and Drug Administration (FDA) approval of Treximet for the acute treatment of migraine attacks. Trudell Medical International announced the FDA approval of Alvesco, a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics